{"schema_version":"1.0","type":"article","title":"核藥賣爆了","url":"https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.md","lang":"zh-Hant","date":"2026-06-01","publish_at":"2026-06-01T10:30:00+08:00","updated_at":"2026-06-01","category":"商業分析系列","topic":"公司研究","tags":["Pluvicto","Novartis","核藥","放射配體療法","攝護腺癌","PSMA","精準治療"],"summary":"Pluvicto 單季銷售達 6.42 億美元，顯示攝護腺癌治療正從荷爾蒙訊號攻防，走向 PSMA 核醫診療一體化與放射配體療法的新階段。","key_points":[],"facts":[],"sections":["單季 6.42 億美元：Pluvicto 把攝護腺癌精準治療推進新階段","01｜攝護腺癌治療的第一條主線：從去勢治療到 AR 抑制劑","02｜AR-V7 暴露了舊戰術的極限","03｜第一條路：PARP 抑制劑，從基因缺陷切入","04｜第二條路：AR 降解劑，從抑制走向清除","05｜第三條路：跳出 AR，找到新的定點殺傷座標","06｜Pluvicto 為什麼能成為「核藥王者」？關鍵不只在藥效，也在供應鏈","07｜全球產業格局：Novartis 領跑，但競爭才剛開始","08｜這和台灣有什麼關係？核醫藥不是空中樓閣，而是正在進入本地臨床","結語｜Pluvicto 的爆發，代表攝護腺癌進入多戰術時代"],"references":[],"images":[{"alt":"Pluvicto 的銷售成長，代表 PSMA 放射配體療法已從小眾核醫技術走向攝護腺癌精準治療主戰場。","url":"https://drugnews.com.tw/assets/articles/pluvicto-radioligand-therapy-growth/dcard-01.webp"},{"alt":"攝護腺癌治療正在從荷爾蒙訊號攻防，走向基因分型、蛋白降解與核醫診療一體化。","url":"https://drugnews.com.tw/assets/articles/pluvicto-radioligand-therapy-growth/dcard-02.webp"},{"alt":"核藥商業化的關鍵，不只在分子設計，也在製造、配送、院端流程與適應症擴張。","url":"https://drugnews.com.tw/assets/articles/pluvicto-radioligand-therapy-growth/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pluvicto-radioligand-therapy-growth/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-01）。核藥賣爆了。https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-01-pluvicto-radioligand-therapy-growth-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}